INCREASED RISK OF TUBERCULOSIS RECURRENCE IN PEOPLE WITH HIV-1 INFECTION (pp 1470, 1488)October 25, 2000People with HIV-1 infection are at an increased risk of recurrent tuberculosis, and could benefit from preventative treatment after the first episode of the disease, concludes research published in this week's issue of THE LANCET. Patients with HIV-1 infection respond well to treatment for active tuberculosis, but whether such patients are at increased risk of disease recurrence after successful treatment is uncertain. As a result, most experts do not recommend more intensive tuberculosis therapy for HIV-1-infected individuals than for uninfected people, and do not recommend prophylaxis after curative treatment. Jean William Pape and colleagues from New York Hospital-Cornell Medical Centre, USA, did a randomised trial in Port au Prince, Haiti, to determine whether recurrent tuberculosis after curative tuberculosis treatment is more common in HIV-1-infected individuals than HIV-1-uninfected individuals, and to determine whether the use of post-treatment isoniazid decreases the risk of recurrent tuberculosis. The investigators assessed patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti. Patients were randomly assigned 1 year of post-treatment isoniazid or placebo, and the primary outcome measure was rate of recurrent tuberculosis after at least two years. Of 274 patients who successfully completed treatment for pulmonary tuberculosis, 233 took part in the study. Of 142 HIV-1-positive patients, 68 were assigned isoniazid and 74 placebo. Of 91 HIV-1-negative individuals, 51 were assigned isoniazid and 40 placebo. The rate of recurrent tuberculosis was 4.8 per 100 person-years in HIV-1-infected individuals and 0.4 per 100 person-years in uninfected individuals. Among HIV-1-positive patients receiving isoniazid, the tuberculosis recurrence rate was 1.4 per 100 person-years, compared with 7.8 among HIV-1-positive patients receiving placebo. Among HIV-1-positive individuals, all cases of recurrent tuberculosis occurred in individuals with a history of HIV-1-related symptoms before initial tuberculosis diagnosis. Jean William Pape comments: "Our study clearly shows that the rate of recurrent tuberculosis is higher in HIV-1-positive individuals than in HIV-1-negative individuals, and is strongly associated with a history of symptomatic HIV-1 disease before initial tuberculosis diagnosis. Post-treatment isoniazid prophylaxis decreases the risk of recurrence in HIV-1-positive individuals, and should be considered for HIV-1-positive individuals with a history of HIV-1-related symptoms at the time of tuberculosis diagnosis". In a research letter also published in THE LANCET this week (p 1488), E Frances Bowen and colleagues from St Georges Hospital, London, UK, report an increased prevalence of HIV-1 infection in people with tuberculosis. In this UK study, tuberculosis patients and their contacts were anonymously tested for HIV. The investigators found that 11% of patients (from various demographic groups) with tuberculosis who attend chest clinics in south London were HIV-1 positive, more than double previous estimates; as the study excluded patients known to be HIV-1 positive, they estimate that the true co-infection rate may be as high as 17-20%. 5% of individuals seen in the tuberculosis-contact screening clinics and 4% of new entrants were HIV-1 positive. The investigators conclude that all patients with tuberculosis, irrespective of background, should be urged to have an HIV test, and point out the serious implications for the provision of currently overstretched health-care facilities for patients with tuberculosis and for asylum seekers. Contact: Dr Warren D Johnson Jr, Division of International Medicine and Infectious Diseases, New York Hospital-Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA; T) +1 212 746 6320; F) +1 212 746 8675; E) wdjohnso@med.cornell.edu Dr Charlotte Rayner, c/o Claire Grant, Public Relations Manager, St Georges Hospital, London, SW17 0QT, UK; T) +44 (0)20 8725 3307; F) +44 (0)20 8725 0239; E) claire.grant@stgh-tr.sthames.nhs.uk Lancet |
|||||||||||||||||||||
| Related Tuberculosis Current Events and Tuberculosis News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. There's a speed limit to the pace of evolution, Penn biologists say Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits." Cell phones become handheld tools for global development Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. Scientists take step toward simple and portable tuberculosis tests for developing world Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||